All In Biotech

Drug Trial Radar · NCT00076388

Iressa Versus Docetaxel (Taxotere)

A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy

Last checked: Nov 19, 2026Latest source record: May 13, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,440 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,440

Actual

Start

Feb 2004

Primary completion

Mar 2007

Study completion Oct 2007

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jan 23, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the effects of ZD1839 or docetaxel in patients with advanced non-small cell lung cancer (NSCLC) that has recurred or progressed after receiving prior treatment with platinum-based chemotherapy.

Conditions

  • Non-Small-Cell Lung Carcinoma

Interventions

  • GefitinibDrug

  • DocetaxelDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare overall survival between ZD1839 and docetaxel

Locations

162 sites in 25 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Fountain Valley, California

  • Research Site

    Los Angeles, California

  • Research Site

    Santa Rosa, California

  • Research Site

    Stockton, California

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Norwich, Connecticut

  • Research Site

    Newark, Delaware

  • Research Site

    Boca Raton, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Macon, Georgia

  • Research Site

    Tucker, Georgia

  • Research Site

    Skokie, Illinois

  • Research Site

    Knoxville, Kentucky

  • Research Site

    Saint Louis Park, Minnesota

  • Research Site

    Great Neck, New York

  • Research Site

    Rochester, New York

  • Research Site

    Syracuse, New York

  • Research Site

    Chapel Hill, North Carolina

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Durham, North Carolina

  • Research Site

    Cleveland, Ohio

  • Research Site

    Portland, Oregon

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Columbia, South Carolina

  • Research Site

    Nashville, Tennessee

  • Research Site

    Austin, Texas

  • Research Site

    Dallas, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Tyler, Texas

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Fairfax, Virginia

  • Research Site

    Seattle, Washington

  • Research Site

    Racine, Wisconsin

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Córdoba, Argentina

  • Research site

    El Palomar, Argentina

  • Research Site

    Mar del Plata, Argentina

  • Research Site

    Quilmes, Argentina

Showing 40 of 162 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.